{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["12(4)"],"submitter":["Van Hout A"],"pubmed_abstract":["The chemokine receptor CXCR4 is activated by its unique chemokine ligand CXCL12 and regulates many physiological and developmental processes such as hematopoietic cell trafficking. CXCR4 is also one of the main co-receptors for human immunodeficiency virus (HIV) entry. Dysfunction of the CXCL12/CXCR4 axis contributes to several human pathologies, including cancer and inflammatory diseases. Consequently, inhibition of CXCR4 activation is recognized as an attractive target for therapeutic intervention. In this regard, numerous agents modifying CXCR4 activity have been evaluated in in vitro experimental studies and pre-clinical models. Here, we evaluated a CXCL12 competition binding assay for its potential as a valuable initial screen for functional and competitive CXCR4 inhibitors. In total,"],"journal":["PloS one"],"pagination":["e0176057"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC5391968"],"repository":["biostudies-literature"],"pubmed_title":["Comparison of cell-based assays for the identification and evaluation of competitive CXCR4 inhibitors."],"pmcid":["PMC5391968"],"pubmed_authors":["Schols D","Van Hout A","Van Loy T","Oeyen M","D'huys T"],"additional_accession":[]},"is_claimable":false,"name":"Comparison of cell-based assays for the identification and evaluation of competitive CXCR4 inhibitors.","description":"The chemokine receptor CXCR4 is activated by its unique chemokine ligand CXCL12 and regulates many physiological and developmental processes such as hematopoietic cell trafficking. CXCR4 is also one of the main co-receptors for human immunodeficiency virus (HIV) entry. Dysfunction of the CXCL12/CXCR4 axis contributes to several human pathologies, including cancer and inflammatory diseases. Consequently, inhibition of CXCR4 activation is recognized as an attractive target for therapeutic intervention. In this regard, numerous agents modifying CXCR4 activity have been evaluated in in vitro experimental studies and pre-clinical models. Here, we evaluated a CXCL12 competition binding assay for its potential as a valuable initial screen for functional and competitive CXCR4 inhibitors. In total,","dates":{"release":"2017-01-01T00:00:00Z","publication":"2017","modification":"2026-05-30T06:44:11.566Z","creation":"2019-03-26T22:53:02Z"},"accession":"S-EPMC5391968","cross_references":{"pubmed":["28410420"],"doi":["10.1371/journal.pone.0176057"]}}